If you have an advanced cancer patient who has exhausted effective treatment options under the NCCN Guidelines, consider enrolling them in a new clinical study. This study may offer a completely new set of treatments, along with test results that indicate which of these new treatments are most likely to be effective for them.
The advantages this clinical study can provide your patients include:
- Access to FDA-approved off-guideline cancer drugs, proven to be safe and effective for other cancer patients.
- Personalized selection of treatments based on diagnostic tests that identify which off-guideline drugs are likely to be most effective.
- Available to virtually every cancer patient with a qualifying diagnostic test, with no travel required: you are the treating oncologist, and the patient will be treated in your hospital.
The benefits this clinical study can offer you include:
- Our Clinical Study Team prepares the scientific report that provides evidence for using the off-guideline drug, relieving you of this research responsibility.
- Our Clinical Study Team writes the medical necessity cover letter for insurance, relieving you of this administrative task.
- Our Clinical Study Team works directly with the healthcare provider (Medicare or private), relieving you of this communication task.
- This study allows you to identify FDA-approved drugs tailored to your patient through diagnostic testing, for those who have no remaining options under the NCCN Guidelines.
Background
Cancer Commons has launched a clinical study (CCCS001 on www.clinicaltrials.gov) that enables advanced cancer patients who have exhausted effective treatments to access FDA-approved off-guideline drugs that are currently unavailable to them under the NCCN Guidelines.
This observational study employs diagnostic tests, both genomic and functional, to pinpoint promising off-guideline drugs for each study participant. The Clinical Study Team will compile a comprehensive analysis of the evidence from the patient's diagnostic test and scientific literature regarding the potential effectiveness of these off-guideline drugs. You will receive this analysis to determine if the off-guideline drugs could be beneficial for your patient.
For a sample Scientific Evidence Report, please visit www.cancercommons.org/sample_report.
To participate in the study, a patient must meet three requirements: (1) they must have a diagnostic test (genomic or DST) indicating that one or more off-guideline drugs might be effective for them, (2) they must have an oncologist willing to administer FDA-approved off-guideline drugs, and (3) they must be able to access the off-guideline drugs, either through their insurance or another method.
The study does not have designated sites. As the treating oncologist, you can administer treatment to the patient at your current hospital.
For more information, please visit www.cancercommons.org/CCCS001
